Orthopaedic implants market: size, growth and outlook 2026–2032

High-value consignment stock where tracking and surgeon-preference items decide cost. Published estimates normalised to 2025 range from USD 26.4 bn to USD 61.4 bn; the Consulting Wallah central estimate is USD 26.5 bn, growing at about 4% a year to USD 36.1 bn by 2032. Scope differences between publishers explain most of the spread — the comparison table below states each one.

Growth is driven by ageing populations and rising osteoarthritis, osteoporosis and fracture incidence (GCC 60+ cohort ~2.6 mn in 2023); obesity and sedentary lifestyles in GCC and India raising joint-disorder prevalence; robotic-assisted surgery adoption (Stryker MAKO >2,000 systems; ~2/3 of US knees robotic at end-2024) and 3D-printed/patient-specific implants.

Context that matters for buyers and suppliers: Global orthopedics sales were ~USD 59 bn in 2024, of which implants ~USD 50 bn (+6%). 2024 revenues: Stryker USD 22.6 bn (+10.2% organic), Zimmer Biomet USD 7.7 bn, Smith & Nephew USD 5.8 bn, Globus ~USD 2.5 bn, Enovis USD 2.1 bn. Knee/hip implant prices fell ~1% in 2024; about 25% of operating rooms have access to an orthopaedic robot. Robot installed bases: Stryker MAKO >2,000; Zimmer ROSA >1,200; S+N CORI >1,000; Globus Excelsius ~500.

The chart shows the Consulting Wallah central estimate: published figures normalised to 2025, median taken, and projected at the median published growth rate. The published range for 2025 is USD 26.4 bn–USD 61.4 bn; differences are mostly scope.

Included: the product category as named, across hospital, clinic, laboratory and home settings, including the consumables and service contracts that travel with it where sources report them together. Excluded: adjacent categories reported in their own markets. Global figures are quoted as published; regional figures are flagged by scope.

Shares as reported by the named sources; ranking is more reliable than the exact percentage.

• Global orthopedics sales were ~USD 59 bn in 2024, of which implants ~USD 50 bn (+6%) (Gabelli)
• 2024 revenues: Stryker USD 22.6 bn (+10.2% organic), Zimmer Biomet USD 7.7 bn, Smith & Nephew USD 5.8 bn, Globus ~USD 2.5 bn, Enovis USD 2.1 bn (Gabelli)
• Knee/hip implant prices fell ~1% in 2024; about 25% of operating rooms have access to an orthopaedic robot (Gabelli)
• Robot installed bases: Stryker MAKO >2,000; Zimmer ROSA >1,200; S+N CORI >1,000; Globus Excelsius ~500 (Gabelli)
• Ortho M&A median multiples: 4.0x revenue, ~12x EBITDA (Gabelli)
• India's 2017 knee implant price cap reportedly cut patient costs by up to 70% (Business Standard)
• Hospitals hold 62% of global orthopedic implant end-use; orthopedic clinics the fastest-growing channel (5.6% CAGR) (Research and Markets)
• UAE healthcare expenditure projected at USD 30.7 bn by 2027 (cited as GCC ortho demand context) (IMARC Group)

Where the GCC and India sit

• GCC orthopedic devices: USD 897.5 mn (2025) -> USD 1,545.1 mn (2034), 6.04% CAGR (2025) — IMARC Group
• UAE share of GCC orthopedic devices: 31.5% (2025) — IMARC Group
• India orthopedic devices: USD 2.8 bn (2025) -> USD 4.6 bn (2034), 5.57% CAGR (2025) — IMARC Group
• India knee replacement volume: >250,000 surgeries per year (2025) — Business Standard
• North America share of global orthopedic implants: 42% (2024) — Research and Markets
• GCC population aged 60+: ~2.6 mn (4.5% of population) (2023) — IMARC Group

Consulting Wallah works this market from both sides: hospital groups in the UAE, Saudi Arabia, India and Bangladesh as buyers, and manufacturers in India, China, Singapore, Malaysia and the US as suppliers through the Network. Our observation is that registration status, in-country stock and structured quotations decide access in the GCC, while price and distributor reach decide it in India. CW observation

Opportunities we see: gCC market growing ~6% with UAE as hub (31.5% share) and Saudi capacity build-out; india market USD 2.8 bn growing 5.6% with >250k knee replacements/yr and local manufacturing (Meril, Alkem-Exactech, Auxein); extremities and sports medicine growing fastest (high-single-digit), consolidation via Paragon 28, LimaCorporate deals.

Key companies named across the sources; local distributors and implementation partners matter as much as the brand in the GCC and India.

• Hospital leaders: standardise the fleet or the product family across sites, tender on total cost of use with fill-rate and uptime KPIs, and dual-source the top lines — see our five-line scoring.
• Suppliers: GS1 data, in-country stock and service response are the differentiators after price; the Consulting Wallah Network carries GCC and Indian demand in this category.
• Investors: regional manufacturing or service capacity backed by procurement preference.

1. Research and Markets / GlobeNewswire, Orthopedic Implants Market and Companies Overview 2025 - A USD 32.4 bn landscape by 2030 — rss.globenewswire.com
2. Gabelli Funds, Orthopedics Market 2025 Update — gabelli.com
3. IMARC Group, GCC Orthopedic Devices Market 2026-2034 — imarcgroup.com
4. IMARC Group, India Orthopedic Devices Market 2026-2034 — imarcgroup.com
5. Business Standard, NPPA extends knee implant price ceiling to November 2026 — business-standard.com
6. Research and Markets (via GlobeNewswire) (2025-05) — USD 25.3 bn (2024) to USD 32.4 bn (2030), CAGR 4.2% (2024-2030); scope: Global orthopedic implants (reconstructive joint, spinal, trauma, dental, orthobiologics); North America 42% share 2024; APAC fastest at 6.4% CAGR — source
7. Gabelli Funds (Orthopedics Market 2025 Update) (2025-04) — USD 59 bn (implants ~USD 50 bn; instruments/equipment USD 9 bn) (2024) to — (), CAGR ~4% p.a. outlook; scope: Global orthopedics (broad: knee/hip USD 17.4 bn, spine USD 11 bn, trauma USD 6.4 bn, sports med ~USD 6.3 bn, extremities USD 6 bn); implants grew 6% in 2024 — source
8. Consulting Wallah Network — anonymised observations from procurement and business-setup work with hospital groups and suppliers in the UAE, India and Bangladesh (2024–26), used for the GCC/India outlook and the “what it means” section.
9. Method. Each published figure is normalised to a 2025 base using its own CAGR; the Consulting Wallah central estimate is the median of the normalised figures (or the stated scope where noted) projected at the median CAGR to 2032. Country figures are quoted as published; where we add a CW estimate it is labelled.